🧾 What This Document Is

This is a 6-K filing, which is a report international companies like Genmab (based in Denmark) submit to the U.S. SEC to announce major events. This specific event is a "Major Shareholder Announcement." It's a formal notification required by Danish law when an investor's ownership crosses a key threshold.

👉 In simple terms: A big investor just publicly disclosed they've bought enough Genmab shares to become a significant owner.

🏢 What The Company Does

Genmab is a biotechnology company focused on creating advanced antibody-based medicines to treat cancer and other serious diseases. Think of them as architects designing very specific biological tools (antibodies) that can target diseases with precision.

They have a 25-year history, eight approved drugs, and a pipeline of new treatments in late-stage testing. They are headquartered in Copenhagen, Denmark, and trade on the Nasdaq in Copenhagen and as an ADR (GNMSF) in the U.S.

📢 The Announcement: A New Major Shareholder

The core of this filing is that Orbis Investment Management Limited has informed Genmab that, as of March 31, 2026, it controls shares representing 5.01% of Genmab's total share capital and voting rights.

• The Number: 3,221,620 shares.
• The Threshold: Crossing the 5% mark is a legal milestone in many markets (including Denmark). It triggers a requirement for public disclosure.
• The Implication: Orbis is now officially a "major shareholder." Their ownership stake gives them a meaningful voice in the company's future.

🤔 Why This Matters To Investors

When a prominent investment manager like Orbis crosses this threshold, the market pays attention for a few reasons:

• Signal of Confidence: It suggests a large, professional investor has done deep research and believes in Genmab's long-term value.
• Potential for Influence: Major shareholders can sometimes influence corporate strategy, especially if they are activist investors (though Orbis is typically known as a long-term, value-oriented investor).
• Increased Scrutiny: Other investors will watch Orbis's next moves closely. Will they buy more, hold, or eventually sell?

👉 This announcement isn't about a business deal or drug result—it's about a shift in the company's ownership structure.

⚖️ Big Picture: Strengths & Context

👍 Strengths Highlighted By This News:

• Genmab's underlying science and pipeline are attracting significant capital from sophisticated investors.
• A diversified, institutional shareholder base adds stability and credibility.

⚠️ Risks & Considerations:

• The filing itself contains a standard disclaimer about "forward-looking statements," reminding us that Genmab's future success depends on clinical trials, regulatory approvals, and commercial execution—all inherently risky in biotech.
• While this news is neutral to positive, it doesn't change the near-term operational challenges or milestones for their drug pipeline.

🔍 What To Watch Next

1. Orbis's Future Actions: Does this 5.01% stake become a larger position? This will be disclosed in future filings if it crosses other thresholds (e.g., 10%).
2. Stock Reaction: While often a minor event, news of increased institutional buying can provide a slight sentiment boost.
3. Company's Response: Genmab's management might privately engage with Orbis to understand their investment thesis and perspective.

🧠 The Analogy

Imagine Genmab is a exclusive, high-tech club. Orbis just bought enough membership points to get their name listed on the club's "Major Members" board. Everyone in the club will now notice them, wonder what projects they might support, and keep an eye on whether they buy even more points.

📇 Key Contacts & People

• Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
  • T: +1 609 524 0065
  • E: [email protected]
• Andrew Carlsen, Vice President, Head of Investor Relations
  • T: +45 3377 9558
  • E: [email protected]

🧩 Final Takeaway

This is a regulatory ownership disclosure, not an operational update. It reveals that a major investment firm, Orbis, has crossed the 5% ownership line in Genmab, signaling their confidence in the biotech's long-term story. For investors, it's a piece of data about ownership structure, reminding them to watch how this stake evolves alongside the company's clinical and commercial progress.